Update: Closing in on commercialization
VolitionRx announced a new commercialization strategy for the US with its FY15 results. The company will seek a 510(k) approval in the US as an intermediate step to eventual PMA approval. This will allow for a quicker commercial launch of the NuQ colorectal test in the US, but would limit its marketing to “informing†a physician’s diagnosis instead of being a definitive diagnostic tool. The nearest-term revenues are in Europe, where a CE-mark approval and commercial launch are slated for late 2016.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.